The FDA approved the original version of Crystalens in 2003, at which time it was developed and marketed by a startup company called eyeonics.Bausch Lomb acquired Crystalens in early 2008; and in June of that year, the FDA approved a “high-definition” version of Crystalens, which incorporates an optic designed for better near vision.IOL developers continue to investigate new accommodating designs in hopes of gaining enough accommodation to provide sharp vision at all distances.A Review of the Current Pipeline THE APPROVED Crystalens® and Trulign® Toric (both by Bausch Lomb) are currently the only FDA-approved IOLs that can be described as accommodating.Multifocal patients often complain of seeing glare and halos, especially at night, in the first few months after surgery.As a result, considerable time and money are being invested in the development of IOLs that reduce or eliminate the problems of current multifocals.
In May 2013, the FDA approved a toric version of the lens, called Trulign.
For nearly two decades, “presbyopia-correcting” intraocular lenses (IOLs) have been available to post-cataract surgery patients, but for a variety of reasons they have garnered only modest interest.
According to , presbyopia-correcting lenses only account for 2.4% of total IOLs implanted globally in 2014.
Typically, the eye’s “focusing” or ciliary muscle powers the movement or shape change.
Currently approved accommodating designs cause less loss of contrast sensitivity and are less likely than multifocal IOLs to produce glare and halos.